Barclays PLC Has $189,000 Stock Position in PepGen Inc. (NASDAQ:PEPG)

Barclays PLC raised its position in PepGen Inc. (NASDAQ:PEPG) by 318.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 21,971 shares of the company’s stock after buying an additional 16,723 shares during the period. Barclays PLC owned 0.07% of PepGen worth $189,000 as of its most recent SEC filing.

Several other large investors have also recently added to or reduced their stakes in the company. Janus Henderson Group PLC raised its holdings in shares of PepGen by 331.2% in the third quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after buying an additional 1,794,641 shares during the last quarter. Suvretta Capital Management LLC lifted its position in shares of PepGen by 9.2% during the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock worth $14,201,000 after purchasing an additional 140,000 shares in the last quarter. Sofinnova Investments Inc. grew its stake in shares of PepGen by 11.4% during the second quarter. Sofinnova Investments Inc. now owns 561,128 shares of the company’s stock valued at $8,956,000 after purchasing an additional 57,504 shares during the last quarter. Walleye Capital LLC acquired a new stake in shares of PepGen in the third quarter valued at approximately $519,000. Finally, Bank of New York Mellon Corp raised its position in PepGen by 43.6% in the 2nd quarter. Bank of New York Mellon Corp now owns 44,157 shares of the company’s stock worth $705,000 after purchasing an additional 13,397 shares during the last quarter. 58.01% of the stock is owned by institutional investors.

PepGen Stock Down 3.9 %

PEPG stock opened at $3.68 on Tuesday. PepGen Inc. has a twelve month low of $2.90 and a twelve month high of $19.30. The company has a market cap of $119.95 million, a P/E ratio of -1.23 and a beta of 1.66. The business’s fifty day moving average is $4.93 and its 200-day moving average is $9.21.

Analysts Set New Price Targets

A number of research analysts have commented on PEPG shares. Wedbush decreased their price objective on PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $26.00 price target on shares of PepGen in a report on Friday, November 8th. Finally, Bank of America cut PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective for the company. in a report on Monday, December 16th.

PepGen Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.